RankAlpha logo
Back to Rankings

CRDL

Cardiol TherapeuticsA
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
The May 7 company update adds publication validation of Phase II MAvERIC data and says the pivotal MAVERIC trial had recently surpassed 75% enrollment [#IR-2026-05-07] [#PR-EARNINGS-2026-05-07]. If enrollment stays on track and later data are clean, the stock can re-rate on de-risking.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Coverage is thin and analyst target count is unavailable, so the $6.97 median target is noisy and may not reflect current conviction.
Momentum
91
Value
41
Sentiment
73
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.05 · Bull $2.75 · Bear $0.48
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-03 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $6.97
Why
Momentum91 · Δ7d -
Value41 · Δ7d +0.1
Sentiment73 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
91
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
73
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade

Composite grade A. Momentum 91.0 / Value 41.1 / Sentiment 72.7

Fundamentals (TTM)
As of 2026-06-01
Market Cap
$136.64M
Beta
0.84
Shares Out
99.49M
P/E (TTM) · Derived
-3.7
P/S (TTM)
-
P/FCF (TTM) · Derived
-6.54
Rev YoY
-
EPS YoY
+35.5%
Gross Margin
-
Op Margin
-
Net Debt
-$22.21M
Current Ratio
3.89
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology